Tenofovir Alafenamide 25 mg TELAVINCE AF25

Tenofovir alafenamide (TAF) 25 mg is a once-daily oral antiviral tablet used to treat chronic hepatitis B virus (HBV) infection and as a component of HIV treatment regimens. It belongs to the nucleotide reverse transcriptase inhibitor (NtRTI) class and works by blocking the enzyme that the virus uses to replicate. Compared to its predecessor tenofovir disoproxil fumarate (TDF), TAF 25 mg delivers the same antiviral potency at a significantly lower dose, resulting in far less exposure to the kidneys and bones — making it the preferred choice for patients with renal concerns or low bone mineral density.

What Is Tenofovir Alafenamide 25 mg?

Tenofovir alafenamide 25 mg is a next-generation antiviral tablet manufactured by Gilead Sciences and marketed globally under the brand name Vemlidy. It is an oral prescription medicine classified as a nucleotide reverse transcriptase inhibitor (NtRTI) — a family of drugs that directly block the enzyme viruses use to copy their genetic material inside human cells.

TAF is a prodrug of tenofovir. This means that when you swallow the tablet, it is not immediately active in its original form. Instead, it is specifically designed to remain stable in the bloodstream and convert into its active form — tenofovir diphosphate — primarily inside the infected liver cells and immune cells where the virus is actually replicating. This targeted delivery mechanism is what makes TAF fundamentally different from and safer than its predecessor, tenofovir disoproxil fumarate (TDF).

TDF, the older formulation, releases tenofovir into systemic blood circulation, where it circulates throughout the body at high concentrations before reaching its target cells. This prolonged systemic exposure was directly linked to two significant long-term toxicities — kidney damage (nephrotoxicity) and reduced bone mineral density (BMD). TAF addresses this problem by delivering approximately 90% lower plasma tenofovir exposure while maintaining the same antiviral effect — a major advancement in antiviral therapy, particularly for patients requiring lifelong treatment.

How Does Tenofovir Alafenamide 25 mg Work?

Understanding the mechanism of TAF helps explain why it is so effective and why it has largely replaced TDF in modern treatment guidelines.

Prodrug Activation: After oral ingestion, TAF is absorbed through the gastrointestinal tract and enters the bloodstream in its prodrug form. Because it is more stable in plasma than TDF, it remains intact as it reaches the liver and target immune cells. Once inside these cells, specific intracellular enzymes — primarily cathepsin A in hepatocytes — cleave the prodrug structure and convert TAF into tenofovir, which is then phosphorylated into its fully active form, tenofovir diphosphate.

Blocking Reverse Transcriptase: Hepatitis B virus and HIV both rely on an enzyme called reverse transcriptase to replicate their genetic material. Tenofovir diphosphate works by competing with the natural nucleotide (deoxyadenosine triphosphate) that the virus uses to build its DNA chain. When tenofovir diphosphate is incorporated instead, it acts as a chain terminator — the viral DNA replication process is halted, new virus copies cannot be completed, and the viral load in the body progressively decreases.

Lower Systemic Exposure: Because TAF delivers the active drug primarily inside cells rather than through systemic circulation, the resulting plasma tenofovir levels are approximately 90% lower than with TDF 300 mg. This directly reduces the drug's impact on the kidneys (which filter blood tenofovir) and on bone mineral density (which is affected by tenofovir's interaction with phosphate metabolism), making long-term treatment substantially safer.

Tenofovir Alafenamide 25 mg Uses — Clinical Applications

Chronic Hepatitis B Virus (HBV) Infection: This is the primary approved indication for TAF 25 mg as a standalone agent. Chronic hepatitis B affects approximately 250 million people worldwide, with a particularly high burden across Asia and Sub-Saharan Africa. TAF 25 mg, taken once daily, significantly reduces HBV DNA levels in the blood, normalises liver enzyme levels (ALT), and helps prevent progressive liver damage including cirrhosis and hepatocellular carcinoma. Clinical trials supporting its approval demonstrated that TAF achieved virological suppression (HBV DNA below 29 IU/mL) in over 94% of treatment-naive patients at 48 weeks.

HIV Treatment — Part of Combination Antiretroviral Therapy (ART): TAF is a foundational component of several fixed-dose HIV combination regimens approved globally. It is co-formulated with emtricitabine, rilpivirine, cobicistat, elvitegravir, bictegravir, and darunavir in various single-tablet HIV treatment regimens. In these combinations, TAF provides the nucleotide backbone that suppresses HIV replication while the companion drugs address the virus through different mechanisms — together achieving and maintaining an undetectable viral load.

Prevention of Mother-to-Child HBV Transmission: Emerging clinical research, including a multicentre Phase 4 randomised controlled trial (NCT04850950), is investigating TAF 25 mg in pregnant women with chronic HBV infection and high viral loads (above 200,000 IU/mL), administered during late pregnancy to prevent perinatal transmission. Early data shows promising safety and efficacy in this high-risk setting.

Switching From TDF to TAF: A well-established use of TAF 25 mg is as a switch therapy for patients who are already virologically suppressed on TDF but have developed or are at risk of kidney function decline or bone mineral density loss. Clinical data consistently demonstrates that switching from TDF to TAF stabilises or improves renal function markers (eGFR, serum creatinine) and bone density while maintaining full virological suppression — without any loss of antiviral efficacy.

Recommended Dosage of Tenofovir Alafenamide 25 mg

When to take it: TAF 25 mg must always be taken with food. Food significantly increases the bioavailability of TAF by slowing gastric transit and enhancing intestinal absorption. Taking it on an empty stomach reduces drug exposure by approximately 40%, which can compromise its antiviral effectiveness.

Never stop abruptly: This is critically important. If you have hepatitis B and stop taking TAF suddenly — without your doctor's guidance — a severe rebound flare of HBV infection can occur. This is known as acute exacerbation of hepatitis B and can cause sudden, serious liver damage. Your doctor will always monitor your liver function for several months after discontinuation.

Benefits of Tenofovir Alafenamide 25 mg

The advantages of TAF 25 mg over older antiviral therapies — particularly TDF — are well-documented across multiple large-scale clinical trials and real-world studies:

• Delivers 90% lower plasma tenofovir exposure than TDF 300 mg at the same antiviral potency
• Significantly better kidney safety profile — less impact on eGFR and serum creatinine over long-term use
• Preserves bone mineral density better than TDF, critical for elderly patients and those on long-term therapy
• Once-daily single tablet improves treatment adherence — directly linked to better virological outcomes
• Effective in patients with mild to moderate renal impairment (CrCl ≥15 mL/min) — no dose adjustment needed
• Maintains antiviral efficacy comparable to TDF in both hepatitis B and HIV settings
• Minimal drug resistance observed in long-term clinical follow-up studies
• Proven safety profile across more than 3,000 HIV patients in clinical switching studies with less than 1% discontinuation due to adverse events

Side Effects of Tenofovir Alafenamide 25 mg Tablet

TAF is generally well-tolerated. The most commonly reported side effects in clinical trials were mild and manageable:

Common side effects:

• Headache
• Nausea
• Fatigue
• Abdominal discomfort or diarrhoea
• Flatulence (gas)
• Back pain

Serious side effects requiring immediate medical attention:

Lactic Acidosis with Hepatic Steatosis: Although rare, NtRTI drugs including TAF can cause a life-threatening buildup of lactic acid in the blood, combined with fatty liver disease. Warning signs include persistent stomach pain, nausea, vomiting, extreme tiredness, muscle weakness, and fast or laboured breathing. Stop the medication immediately and seek emergency care if these symptoms appear.

Severe Hepatitis B Flare on Discontinuation: As mentioned above, sudden stopping of TAF in hepatitis B patients can trigger a dangerous rebound flare with rapidly worsening liver function. Never self-discontinue this medication.

Worsening Kidney Function: Though TAF has a better renal profile than TDF, regular monitoring of kidney function (eGFR, urine protein) is still recommended throughout treatment, especially in patients with pre-existing renal conditions.

Immune Reconstitution Inflammatory Syndrome (IRIS): In HIV patients starting ART for the first time, the recovering immune system can sometimes mount an exaggerated response to pre-existing infections, causing worsening symptoms shortly after treatment begins. This requires medical evaluation.

Precautions Before Taking Tenofovir Alafenamide 25 mg

• Always inform your doctor if you have kidney disease, liver disease, or a history of lactic acidosis before starting
• Patients with both HBV and HIV must use TAF as part of a complete HIV treatment regimen — using it alone in this setting risks developing HIV drug resistance
• Avoid taking with drugs that strongly induce P-glycoprotein (P-gp) or CYP enzymes such as rifampicin, carbamazepine, or St. John's Wort, as these significantly reduce TAF plasma levels and antiviral effectiveness
• Regular monitoring of HBV DNA levels, liver function tests (ALT, AST), and kidney function (eGFR) is mandatory throughout treatment
• Do not take with certain HIV drugs (particularly older protease inhibitors without boosting) without specific dosing guidance from your physician
• Pregnancy: TAF is being studied in pregnancy for HBV suppression — use only under close medical supervision and discuss risks and benefits thoroughly with your doctor

Frequently Asked Questions (FAQs)

Q1. What is tenofovir alafenamide 25 mg used for?

Ans. Treats chronic hepatitis B and HIV as daily antiviral therapy.

Q2. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate?

Ans.  Yes, TAF causes 90% less kidney and bone toxicity.

Q3. When should tenofovir alafenamide 25 mg be taken?

Ans.  Once daily, always with food for best absorption.